GSA Capital Partners LLP bought a new stake in iRadimed Corporation (NASDAQ:IRMD – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 7,063 shares of the medical equipment provider’s stock, valued at approximately $675,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. CWM LLC grew its position in shares of iRadimed by 19.5% in the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 107 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in iRadimed by 4.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after purchasing an additional 267 shares during the last quarter. Quantinno Capital Management LP increased its position in iRadimed by 12.5% in the 1st quarter. Quantinno Capital Management LP now owns 3,482 shares of the medical equipment provider’s stock valued at $335,000 after acquiring an additional 387 shares during the period. Finally, Farther Finance Advisors LLC increased its holdings in shares of iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares during the period. 92.34% of the stock is owned by institutional investors.
Insider Activity at iRadimed
In other news, CEO Roger E. Susi sold 2,500 shares of iRadimed stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total value of $226,500.00. Following the transaction, the chief executive officer owned 2,162,500 shares of the company’s stock, valued at $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Get Our Latest Report on iRadimed
iRadimed Price Performance
Shares of NASDAQ IRMD opened at $87.40 on Thursday. The company has a market capitalization of $1.12 billion, a P/E ratio of 48.83 and a beta of 0.90. The business’s 50-day moving average price is $93.69 and its two-hundred day moving average price is $94.62. iRadimed Corporation has a one year low of $67.84 and a one year high of $107.90.
iRadimed (NASDAQ:IRMD – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The firm had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities analysts anticipate that iRadimed Corporation will post 1.98 EPS for the current year.
iRadimed Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is currently 44.69%.
iRadimed Profile
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Featured Stories
- Five stocks we like better than iRadimed
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD – Free Report).
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
